Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly

Hepatology

Volumn 59, Issue 6, 2014, Pages 2207-2215

  Chiang, Chien Hsieh ^a   Lee, Long Teng ^a   Hung, Shou Hung ^a   Lin, Wen Yuan ^b,c   Hung, Hui Fang ^a   Yang, Wei Shiung ^a,d   Sung, Pei Kun ^e   Huang, Kuo Chin ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e MJ Health Screening Center   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; DEATH; DEATH CERTIFICATE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL SOCIETY; METABOLIC SYNDROME X; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84901625756     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27014     Document Type: Article

References (37)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2. Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11, 801 men in Taiwan. PLoS One 2012;7:e34779.
3. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012;104:1599-1611.
4. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-121.
5. Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, et al. Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 2009;20:741-750.
6. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006;43:1295-1302.
7. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-539.
8. Brower V. Illuminating the diabetes-cancer link. J Natl Cancer Inst 2012;104:1048-1050.
9. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012;28:109-122.
10. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W, et al. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 2013;8:e54242.
11. Lin WY, Tsai SL, Albu JB, Lin CC, Li TC, Pi-Sunyer FX, et al. Body mass index and all-cause mortality in a large Chinese cohort. CMAJ 2011;183:E329-E336.
12. Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012;60:730-737.
13. Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol 2000;29:336-343.
14. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
15. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-2944.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
17. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-1062.
18. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-592.
19. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer 2010;46:744-751.
20. Chiang CH, Lai JS, Sheu JC, Yen LL, Liu CJ, Huang KC. The risky body mass index ranges for significant hepatitis B viral load: a campus-based study. Obes Res Clin Pract 2012;6:e31-e38.
21. Chiang CH, Yang HI, Jen CL, Lu SN, Wang LY, You SL, et al. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond) 2013;37:410-415.
22. Chiang CH, Lai JS, Hung SH, Lee LT, Sheu JC, Huang KC. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Springs) 2013;21:291-296.
23. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 2012;55:948-958.
24. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651-5661.
25. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
26. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012;32:30-38.
27. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010;58:783-787.
28. Huang KC, Lee LT, Chen CY, Sung PK. All-cause and cardiovascular disease mortality increased with metabolic syndrome in Taiwanese. Obesity (Silver Springs) 2008;16:684-689.
29. Yamasaki D, Kawabe N, Nakamura H, Tachibana K, Ishimoto K, Tanaka T, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur J Cell Biol 2011;90:657-664.
30. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-630.
31. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514-1521.
32. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012;57:1773-1781.
33. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323-332.
34. Chiang CH, Ni YH. Obscure clinical implication of occult hepatitis B virus infection by perinatal transmission despite prophylaxis with hepatitis B vaccination and HBIG [Letter]. J Hepatol 2012;57:1401.
35. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64-S71.
36. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:881-891; quiz 892.
37. Marchesini G, Forlani G. Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia. Hepatology 2012;55:1298-1300.